Agonist News and Research

RSS

What are the effects of smoking cessation on vascular endothelial function?

The effects of smoking cessation on vascular endothelial function.

16 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Researchers discuss the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of diabetes.

5 Oct 2023

Radiation therapy combined with two types of immunotherapy could be effective against cold tumors

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy-;one that boosts T cells, and another that boosts dendritic cells-;can control tumors in preclinical models of triple negative breast cancer, a cancer type that's typically resistant to immunotherapy alone.

25 Sep 2023

Research could lead to the development of new weight-loss drug that mimics exercise

A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise.

25 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Whether patients with newly diagnosed osteoporosis received delayed pharmacologic treatment due to the COVID-19 pandemic.

18 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Rethinking menopause: Experts call for individualized treatment and more research

A comprehensive review in the journal Cell provides an in-depth look at the biology, clinical outcomes, and treatment options for menopause, including the effects of hormonal changes on metabolic and cognitive functions. The article also discusses various therapeutic interventions, from hormone therapy to alternative medicines, and their efficacy in managing menopausal symptoms.

7 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

Study shows how cancer can selfishly hijack a helpful immune pathway to spread

A study led by researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, and shows how cancer can selfishly hijack a normally helpful immune pathway.

23 Aug 2023

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

According to the National Institutes of Health, approximately 24% of adults in the United States have nonalcoholic fatty liver disease (NAFLD), an umbrella term for a range of liver conditions affecting people who drink little to no alcohol that can lead to cirrhosis, liver cancer and liver failure.

23 Aug 2023

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

From Rapid Novor Inc 23 Aug 2023

Study explores mechanism behind liraglutide-associated weight loss in obese individuals

A new study suggests that liraglutide is associated with the normalization of associative learning in obese individuals with insulin resistance.

22 Aug 2023

New microneedles could monitor melanoma therapy response

Patients with melanoma, the most concerning form of skin cancer in which pigment-producing cells start to grow out of control, can benefit from existing immunotherapies, but by far not all of them do.

21 Aug 2023

Obesity impairs brain's ability to learn associations

To control our behavior, the brain must be able to form associations. This involves, for example, associating a neutral external stimulus with a consequence following the stimulus (e.g., the hotplate glows red - you can burn your hand).

17 Aug 2023

Study: 93 million U.S. adults may benefit from semaglutide medication

Researchers from the University of California, Irvine have just published a study that projects 93 million U.S. adults that are overweight and obese may be suitable for the 2.4 mg dosage of semaglutide, a weight loss medication known under the brand name Wegovy.

16 Aug 2023

Unveiling α1-AR secrets: breakthrough structures and targeted drug design

Researchers explored the structural basis of agonist specificity of α1A-adrenergic receptors (α1-ARs).

14 Aug 2023

Agonist News and Research

What are the effects of smoking cessation on vascular endothelial function?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Radiation therapy combined with two types of immunotherapy could be effective against cold tumors

Research could lead to the development of new weight-loss drug that mimics exercise

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Rethinking menopause: Experts call for individualized treatment and more research

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Semaglutide could be a game-changer for patients with HFpEF and obesity

Study shows how cancer can selfishly hijack a helpful immune pathway to spread

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

Study explores mechanism behind liraglutide-associated weight loss in obese individuals

New microneedles could monitor melanoma therapy response

Obesity impairs brain's ability to learn associations

Study: 93 million U.S. adults may benefit from semaglutide medication

Unveiling α1-AR secrets: breakthrough structures and targeted drug design

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News